Thursday, April 25, 2024 Nigeria Launches Large-scale Meningitis Vaccine Campaign, in Decision Based Partly on NIAID-funded Study Illustration of paired cells of Neisseria meningitidis bacteria (orange). Credit: Adobe Stock To combat deadly meningitis outbreaks, Nigeria launched an effort to vaccinate one million people with a vaccine called Men5CV, which protects against five groups of the meningitis pathogen Neisseria meningitidis. The WHO recommended the vaccine for campaigns in the country, a part of "Africa's meningitis belt," based partly on positive interim results from a trial run by the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC). Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107